Skip to main content
. 2009 Aug 17;30(9):1316–1322. doi: 10.1038/aps.2009.119

Figure 2.

Figure 2

Rosiglitazone's contribution to the anti-tumor effect of 5-FU by the PPARγ signaling pathway. (A) Cellular protein was isolated from BEL-7402 cells transfected with control or PPARγ siRNA for 48 h and was then subjected to Western blotting analysis for PPARγ protein. PPARγ siRNA inhibits PPARγ protein expression. (B) BEL-7402 cells were transfected with control or PPARγ siRNA for 48 h before exposing the cells to rosiglitazone (30 μmol/L) in the presence or absence of 5-FU (10 μmol/L). Afterwards, the cell viabilities were determined by MTT assay up to 48 h. Data are expressed as the mean±SD of three independent experiments. bP<0.05 vs control group; Con, cells treated with 0.1% DMSO; Con siRNA, non-specific siRNA, as a negative control.